NEW ISSUE
A State of the Art on cardiogenic shock; a trial of balloon-based techniques for calcified lesions; a mini focus on spontaneous coronary artery dissection, and more…
August 27, 2021
Showing 1-20 of 37 articles
High bleeding risk patients: one size does not fit all
June 25, 2021 | 10.4244/EIJV17I3A35
Entrapment of the Impella heart pump in the mitral subvalvular apparatus
February 5, 2021 | 10.4244/EIJ-D-19-00942
Adverse events with orbital atherectomy: an analytic review of the MAUDE database
July 17, 2020 | 10.4244/EIJ-D-19-00295
Bioresorbable scaffolds: did we jump the gun?
June 12, 2020 | 10.4244/EIJV16I2A16
Coronary interventions
Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial February 7, 2020 | 10.4244/EIJ-D-18-01000
Coronary interventions
BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months December 6, 2019 | 10.4244/EIJ-D-18-01214
Reply to the letter to the editor “Impella device use in high-risk PCI”
October 18, 2019 | 10.4244/EIJ-D-19-00279R
Adverse events and modes of failure related to the Impella percutaneous left ventricular assist devices: a retrospective analysis of the MAUDE database
May 20, 2019 | 10.4244/EIJ-D-18-01021
Comparison of acute thrombogenicity for magnesium versus stainless steel stents in a porcine arteriovenous shunt model
January 18, 2019 | 10.4244/EIJ-D-17-00958
Stents and scaffolds
Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds October 12, 2018 | 10.4244/EIJ-D-17-00708
Coronary interventions
Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III July 20, 2017 | 10.4244/EIJ-D-17-00254
Coronary interventions
Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model July 20, 2017 | 10.4244/EIJ-D-16-00915
Coronary interventions
Does acute coronary syndrome impact on the incidence of thrombosis after the implantation of an Absorb bioresorbable vascular scaffold? March 20, 2017 | 10.4244/EIJ-D-16-00472
Coronary interventions
Chipping of calcified plaques by orbital atherectomy systems, but holding approval tight: is the FDA moving faster than the European CE agency? A North American perspective October 20, 2016 | 10.4244/EIJV12I9A178
Coronary interventions
Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016 September 18, 2016 | 10.4244/EIJV12I7A137
Coronary interventions
Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial June 10, 2016 | 10.4244/EIJ-D-15-00371
Interventions for valvular disease
The adjunctive use of Angio-Seal in femoral vascular closure following percutaneous transcatheter aortic valve replacement May 16, 2016 | 10.4244/EIJV12I1A16
The effect of complete percutaneous revascularisation with and without intravascular ultrasound guidance in the drug-eluting stent era
October 20, 2015 | 10.4244/EIJV11I6A124